|本期目录/Table of Contents|

[1]杨辛怡综述,季国忠审校.幽门螺杆菌感染的治疗方案[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):280-284.[doi:10.3969/j.issn.1672-271X.2017.03.015]
点击复制

幽门螺杆菌感染的治疗方案()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年03期
页码:
280-284
栏目:
综述
出版日期:
2017-05-20

文章信息/Info

Title:
-
作者:
杨辛怡综述; 季国忠审校
作者单位：210011南京, 南京医科大学第二临床医学院(南京医科大学第二附属医院)消化医学中心
Author(s):
-
关键词:
幽门螺杆菌; 抗生素; 佐剂; 疫苗; 新兴疗法
Keywords:
-
分类号:
R57
DOI:
10.3969/j.issn.1672-271X.2017.03.015
文献标志码:
A
摘要:
幽门螺杆菌是目前已知能长期在胃内定植的细菌。幽门螺杆菌感染是消化不良、慢性胃炎、消化性溃疡、胃癌等疾病的重要病因。文章综述了国内外治疗幽门螺杆菌感染的不同方案，分析比较了不同方案的优劣点，并对未来的发展和研究方向进行展望。
Abstract:
-

参考文献/References:

[1]Mégraud F. A humble bacterium sweeps this years Nobel Prize[J]. Cell, 2005, 123(6): 975-976.
[2]Salama N, Guillemin K, McDaniel TK, et al. A whole-genome micro-array reveals genetic diversity among Helicobacter pylori strains[J]. Proc Natl Acad Sci USA, 2000, 97(26): 14668-14673.
[3]European Helicobacter Pylori Study Group. Current european concepts in the management of Helicobacter pylori infection[J]. Gut, 1997, 41(1): 8-13.
[4]Malfertheiner P, Megraud F, OMorain C, et al. Current european concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report[J]. Gut, 2007, 56(6): 772-781.
[5]Metanat HA, Valizadeh SM, Fakheri H, et al. Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication: a randomized clinical trial[J]. Helicobacter, 2015, 20(4): 299-304.
[6]Calvet X, Gené E, López T, et al. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis[J]. Aliment Pharmacol Ther, 2001, 15(7): 1067-1076.
[7]Liou JM, Chen CC, Lee YC, et al. Taiwan Gastrointestinal Disease and HelicobacterConsortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection[J]. Aliment Pharmacol Ther, 2016, 43(4): 470-481.
[8]Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication[J]. Cochrane Database Syst Rev, 2013, 12(12):CD008337.
[9]Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults[J]. Gastroenterology, 2016, 151(1): 51-69.
[10]Hu Y, Zhang M, Lu B, et al. Helicobacter pylori and antibiotic resistance, a continuing and intractable problem[J]. Helicobacter, 2016, 21(5): 349-363.
[11]Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12(4): 275-278.
[12]Malfertheiner P, Megraud F, OMorain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report[J]. Gut, 2012, 61(5): 646-664.
[13]Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis[J]. Helicobacter, 2008, 13(6): 532-541.
[14]McLellan RA, Drobitch RK, Monshouwer M, et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human[J]. Drug Metab Dispos, 1996, 24(10): 1134-1138.
[15]Nagaraja V, Eslick GD. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review[J]. World J of Gastroenterol, 2014, 20(40): 14527-14536.
[16]Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric PH during dosing with lansoprazole or rabeprazole[J]. Aliment Pharmacol Ther, 2000, 14(10): 1259-1266.
[17]Liu X, Wang H, Lv Z, et al. Rescue therapy with a proton pump inhibitor plus amoxicillin and rifabutin for Helicobacter pylori infection: a systematic review and meta-analysis[J]. Gastroenterol Res Pract, 2015, 2015: 1-11.
[18]刘文忠, 谢勇, 成虹,等. 第四次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2012, 51(10): 832-837.
[19]Gu LY, Lin WW, Lu H, et al. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study[J]. Helicobacter, 2011, 16(4): 284-288.
[20]Losurdo G, Leandro G, Principi M, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by ‘geographical weighting’[J]. Int J Clin Pract, 2015, 69(10): 1112-1120.
[21]Dolapcioglu C, Koc-Yesiltoprak A, Ahishali E, et al. Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting[J]. Int J Clin Exp Med, 2014, 7(8): 2324-2328.
[22]Gao XZ, Qiao XL, Song WC, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication[J].World J Gastroenterol, 2010, 16(34): 4357-4362.
[23]Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis[J]. World J Gastroenterol, 2015, 21(45): 12954-12962.
[24]Dolapcioglu C, Sayiner M, Akkus EE, et al. First-line bismuth-containing five-day concomitant quintuple therapy for Helicobacter pylori eradication[J]. Helicobacter, 2016, 21(2): 100-105.
[25]Zhang MM, Qian W, Qin YY, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis[J]. World J Gastroenterol, 2015, 21(14): 4345-4357.
[26]Wolvers D, Antoine JM, Myllyluoma E, et al. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics[J]. J Nutr, 2010, 140(3): 698S-712S.
[27]Hsieh PS, Tsai YC, Chen YC, et al. Eradication of Helicobacter pylori infection by the probiotic strains lactobacillus johnsonii MH-68 and L.salivarius ssp.salicinius AP-32[J]. Helicobacter, 2012, 17(6): 466-477.
[28]Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy[J]. World J Gastroenterol, 2014, 20(47): 18013-18021.
[29]Zou J, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy[J]. Helicobacter, 2009, 14(2): 119-127.
[30]Wang Y, Wang B, Lv ZF, et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis[J]. Helicobacter, 2014, 19(5): 372-381.
[31]Yoon H, Lee DH. Mucolytics as adjuvant agent to improve Helicobacter pylori eradication rate: still long and winding road to positive results[J]. Gut Liver, 2015, 9(3): 257-258.
[32]Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience[J]. World J Gastroenterol, 2014, 20(3): 699-705.
[33]Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: inevitable approach[J]. World J Gastroenterol, 2016, 22(11): 3150-3157.
[34]Müller A, Solnick JV. Inflammation, Immunity, and Vaccine development for Helicobacter pylori[J]. Helicobacter, 2011, 16(1): 26-32.
[35]Liu KY, Shi Y, Luo P, et al. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model[J]. Vaccine, 2011, 29(38): 6679-6685.
[36]Tang RX, Luo DJ, Sun AH, et al. Diversity of H.pylori isolates in expression of antigens and induction of antibodies[J]. World J Gastroenterol, 2008, 14(30): 4816-4822.
[37]Kabir S. The current status of Helicobacter pylori vaccines: a review[J]. Helicobacter, 2007, 12(2): 89-102.
[38]Sutton P, Chionh YT. Why cant we make an effective vaccine against Helicobacter pylori? [J], Helicobacter, 2013, 12(4): 433-441.
[39]Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2015, 386(10002): 1457-1464.
[40]Wainwright M. Photodynamic antimicrobial chemotherapy (PACT)[J]. J Antimicrob Chemother, 1998, 42(1): 13-28.
[41]Moon YH, Kwon SM, Kim HJ, et al. Efficient preparation of highly pure chlorin e6 and its photodynamic anti-cancer activity in a rat tumor model[J]. Oncol Rep, 2009, 22(5): 1085-1091.
[42]Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? [J] Photochem Photobiol Sci, 2004, 3(5): 436-450.
[43]Hamblin MR, Viveiros J, Yang C, et al. Helicobacter pylori accumulates photoactive porphyrins and is killed by visible light[J]. Antimicrob Agents Chemother, 2005, 49(7): 2822-2827.
[44]Choi SS, Lee HK, Chae HS. In vitro photodynamic antimicrobial activity of methylene blue and endoscopic white light against Helicobacter pylori 26695[J]. J Photochem Photobiol B, 2010, 101(3): 206-209.
[45]Simon C, Mohrbacher C, Hüttenberger D, et al. In vitro studies of different irradiation conditions for Photodynamic inactivation of Helicobacter pylori[J]. J Photochem Photobiol B, 2014, 141: 113-118.
[46]Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections[J]. Int J Antimicrob Agents, 2007, 30(2): 118-128.
[47]Lehours P, Vale FF, Bjursell MK, et al. Genome sequencing reveals a phage in Helicobacter pylori[J]. MBio, 2011, 2(6): e00239-11.
[48]Luo CH, Chiou PY, Yang CY, et al. Genome, integration, and transduction of a novel temperate phage of Helicobacter pylori[J]. J Virol, 2012, 86(16): 8781-8792.
[49]Uchiyama J, Takeuchi H, Kato S, et al. Complete genome sequences of two Helicobacter pylori bacteriophages isolated from Japanese patients[J]. J Virol, 2012, 86(20): 11400-11401.
[50]Lukacik P, Barnard TJ, Keller PW, et al. Structural engineering of a phage lysin that targets Gram-negative pathogens[J]. Proc Natl Acad Sci USA, 2012, 109(25): 9857-9862.
[51]Middleton E Jr, Kandaswami C, Theoharides TC. The Effects of plant flavonoids on Mammalian cells: implications for inflammation, heart disease, and cancer[J]. Pharmacol Rev, 2000, 52(4): 673-751.
[52]Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori[J]. World J Gastroenterol, 2014, 20(19): 5594-5609.
[53]Pastene E, Speisky H, García A, et al. In Vitro and in Vivo Effects of Apple Peel Polyphenols against Helicobacter pylori[J].J Agric Food Chem, 2010, 58(12): 7172-7179.
[54]Asha MK, Debraj D, Prashanth D, et al. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action[J]. J Ethnopharmacol, 2013, 145(2): 581-586.
[55]Martini S, Bonechi C, Rossi C, et al. Increased Susceptibility to Resveratrol of Helicobacter pylori Strains Isolated from Patients with Gastric Carcinoma[J].J Nat Prod, 2011, 74(10): 2257-2260.
[56]Sintara K, Thong-Ngam D, Patumraj S, et al. Curcumin suppresses gastric NF-κB activation and macromolecular leakage in Helicobacter pylori-infected rats[J]. World J Gastroenterol, 2010, 16(32): 4039-4046

相似文献/References:

[1]舒荣文,顾佳云,孔庆军.枸橼酸铋雷尼替丁为基础治疗萎缩性胃炎患者Hp的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):27.
　SHU Rong-wen,GU Jia-yun,KONG Qing-jun..Observation of curative effect of ranitidine bismuth citrate based triple therapies for eradication of Helicobacter pylori infection in chronic atrophic gastritis patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(03):27.
[2]叶 明,杨喜民,王 刚,等.耐碳青霉烯类铜绿假单胞菌的产酶及联合药敏试验[摘要][J].医学研究与战创伤救治(原医学研究生学报),2011,13(02):135.
　YE Ming,YANG Xi-min,WANG Gang,et al.The analysis of zymogenic state against Carbapenems-resistant Pseudomonas aeruginosa using a susceptibility test[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(03):135.
[3]杨 燕,孙长贵,陈 坚,等.用改良Hodge试验检测产碳青霉烯酶肠杆菌科细菌[J].医学研究与战创伤救治(原医学研究生学报),2011,13(03):223.
　YANG Yan,SUN Chang-gui,CHEN Jian,et al.Detection of carbapenemase in isolates of Enterobacteriaceae by the modified Hodge test[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(03):223.
[4]朱 云,张南征,马文青,等.根除幽门螺杆菌对降低部队官兵消化性溃疡复发率的价值[J].医学研究与战创伤救治(原医学研究生学报),2011,13(04):294.
　ZHU Yun,ZHANG Nan-zheng,MA Wen-qing,et al.The study on the reduction of the peptic ulcers recurrence rate in soldiers after H.pylori eradication[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(03):294.
[5]李志晋,詹丽英,马春曦,等.白细胞介素-4对幽门螺杆菌根除的影响[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):534.
[6]陶瑛瑛,马爱华,倪江洪.夫西地酸钠的配伍禁忌及处理方法[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):257.
[7]韩清萍,刘秀娟,余燕燕.头孢菌素致尿毒症患者神经毒性36例分析及护理[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):266.
[8]郎根强,章益峰,褚 健,等.[1]庄颜峰，吕 琦，陈学明，等. 严重骨盆骨折的初期救治体会[J]. 中华创伤骨科杂志，2004,6(5):582-583.[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):493.
　LANG Gen-qiang,ZHANG Yi-feng,CHU Jian,et al.Treatment of chronic prostatitis with ectoshortwave, antibiotics and prostant[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):493.
[9]潘雪飞,杜 斌,范 群,等.综合分析药物性肝损伤4 076例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):505.
　PAN Xue-fei,DU Bin,FAN Qun,et al.The statistic analysis of the 4 076 patients with drug induced liver injury[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):505.
[10]刘 冉,张世联,牟振云,等.牛乳中抗幽门螺杆菌特异性抗体的 间接ELISA法的建立[J].医学研究与战创伤救治(原医学研究生学报),2008,10(03):174.
　LIU Ran,ZHANG Shi-lian,MOU Zhen-yun,et al.Development of indirect enzyme-linked immunosorbent assay(ELISA) for detection of anti-Helicobacter pylori antibodies from bovine immune milk[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(03):174.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2017-05-20